Cost-efficacy evaluation of a mindfulness-based program added to treatment as usual for the treatment of chronic migraine associated to medication overuse headache
Abstract
BACKGROUND: Chronic Migraine associated to Medication Overuse Headache (CM-MOH) causes considerable costs in reason of healthcare costs and loss of productivity. Recently, a mindfulness-based program added to treatment as usual (TaU) proved efficacy compared to TaU alone in patients with CM-MOH. This study aims to assess the cost-efficacy of such multimodal treatment protocol. METHODS: Patients with CM-MOH filled in a specific protocol aimed to assess direct healthcare costs, direct non-medical costs, and indirect costs, referred to the three months before starting the treatment protocol. Repeated measure analyses were employed to compare total costs’ reductions between the two group of patients. Then, we compared the delta in total costs after allocation to the two treatment arms using the independent-sample t-test. RESULTS: 154 patients completed the 12-months follow-up. Over the period, CM-MOH cost was reduced from 2620€ (95% CI: 2146–3094€) to 1603€ (95% CI: 1182–2023€) in the TaU group, and from 2978€ (95% CI: 2293–3656€) to 752€ (95% CI: 539–965€) in the TaU + MIND group. The time*group interaction analysis on cost reduction indicated a significant difference (F = 2.953,149; p =.035) with a moderate effect size (partial η2 = 0.056). The average difference on one-year cost after randomization was 2582€ favoring patients in the TaU + MIND group: such a figure is higher than the reimbursement from the Lombardia Region Health System for mindfulness-based sessions…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 154 participants or records.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.